Last reviewed · How we verify
GS-7340
GS-7340, a novel prodrug of tenofovir, is under development by Gilead Sciences for the treatment of HIV-1. It aims to improve safety and efficacy over existing tenofovir formulations. Currently in Phase 2 and 3 trials, GS-7340 shows promise in combination regimens and has potential for broader use in HIV management.
At a glance
| Generic name | GS-7340 |
|---|---|
| Also known as | TAF, Tenofovir Alafenamide |
| Sponsor | Gilead Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Any Event in SOC
- Creatinine renal clearance decreased
- Haemoglobin decreased
- Neutrophil count decreased
- Alanine aminotransferase increased
- Blood creatine phosphokinase increased
- Headache
- Blood creatinine increased
- Nasopharyngitis
- Diarrhoea
- Pregnancy
- Aspartate aminotransferase increased
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GS-7340 CI brief — competitive landscape report
- GS-7340 updates RSS · CI watch RSS
- Gilead Sciences portfolio CI